AIDS Therapies

Efavirenz Provides Greater Long-Term Viral Suppression

Published in AIDS Weekly, August 13th, 2001

DuPont Pharmaceuticals presented data showing that combination therapy with its anti-HIV drug Sustiva^TM (efavirenz), a non-nucleoside reverse transcriptase inhibitor (NNRTI), continues to provide greater and more durable viral suppression through three years of follow-up than combination therapy using a protease inhibitor.

Data, presented at the 1st International AIDS Society (IAS) Conference on HIV Pathogenesis and Treatment, showed a greater response in reduction of viral load with a regimen containing Sustiva to less than 50 copies/mL (52%; 78/154) compared with a protease inhibitor-containing regimen (30%; 43/148). The difference was statistically...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2001-08-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry